search
Back to results

Pharmacokinetics of Atropine Oral Gel

Primary Purpose

Cerebral Palsy, Sialorrhea

Status
Recruiting
Phase
Early Phase 1
Locations
United States
Study Type
Interventional
Intervention
Atropine sulfate gel (0.01%)
Sponsored by
University of Utah
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cerebral Palsy focused on measuring Pharmacokinetics, Cerebral Palsy, Sialorrhea, Atropine sulfate gel

Eligibility Criteria

18 Years - 50 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Provide written informed consent and authorization.
  2. Study participants must be able to complete consent, and all study evaluations written in the English language.

Exclusion Criteria:

  1. Female subjects who are pregnant or nursing at the time of screening
  2. Chemotherapy or radiotherapy treatment within the last three months
  3. Severe renal impairment defined as estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2 calculated using the CKD-EPI creatinine equation:

    eGFR (mL/min/1.73 m2) = 141 x min(Scr/k, 1)α x max(Scr/k,1)-1.209 x 0.993Age x 1.018 [if female] x 1.159 [if black]

    Where,

    1. k=0.7 if female
    2. k=0.9 if male
    3. α=-0.329 if female
    4. α=-0.411 if male
    5. min=The minimum of Scr/k or 1
    6. max=The maximum of Scr/k or 1
    7. Scr = serum creatinine (mg/dL)
  4. Acute hepatitis in the prior 6 months, a prior history of cirrhosis, acute hepatic failure, or acute decompensation of chronic hepatic failure; and/or any of the following blood test results, for any individual, when assessed for eligibility:

    1. Bilirubin > 3 x upper limit of normal (ULN). [ULN for bilirubin = 1.4 mg/dL]
    2. Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) > 3 x ULN values used by the laboratory performing the test. [ULN for AST = 40 U/L, ULN for ALT = 60 U/L]
    3. Alkaline phosphatase (ALP) > 3 x ULN [ULN for ALP = 126 U/L)
  5. Deforming lesions of the oral cavity
  6. Previous head and/or neck radiotherapy
  7. Patients with a history of hypersensitivity reaction towards atropine and/or Carbopol 980 NF or any carbomers
  8. Patients with heart conditions such as congenital heart disease, heart failure, coronary heart disease, myocardial infarction, and arrhythmia
  9. Patients with acute glaucoma that may be exacerbated with atropine administration.
  10. Patients with partial pyloric stenosis or other diseases related to gastrointestinal obstruction.
  11. Patients diagnosed with urinary retention
  12. Treatment with any other investigational drug during the 30 days prior to enrollment into the study
  13. Patients receiving anticholinergic medications at baseline.
  14. Patients who are receiving immunosuppression
  15. Patients who are actively being treated for an infection
  16. Patients with a history of salivary gland obstruction or stones
  17. Patients with a history of chronic lung disease or chronic obstructive pulmonary disease (COPD)
  18. Patients with an artificial airway (tracheostomy)
  19. Patient taking monoamine oxidase inhibitors

Sites / Locations

  • University of UtahRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

0.1 mg of atropine

Arm Description

1 gram of gel by topical application in the oral cavity once.

Outcomes

Primary Outcome Measures

Evaluate pharmacokinetic parameter time to reach maximum plasma concentration (Tmax) in healthy adults to see if atropine will reach detectable concentrations in plasma following topical oral administration in gel formulation.
Calculate the pharmacokinetic parameter Tmax after topical oral administration of 0.01% atropine gel.
Evaluate pharmacokinetic parameter time to reach maximum plasma concentration (Cmax) in healthy adults to see if atropine will reach detectable concentrations in plasma following topical oral administration in gel formulation.
Calculate the pharmacokinetic parameter Cmax after topical oral administration of atropine gel
Evaluate pharmacokinetic parameter area under the curve (AUC) in healthy adults to see if atropine will reach detectable concentrations in plasma following topical oral administration in gel formulation.
Calculate the pharmacokinetic parameter AUC after topical oral administration of atropine gel
Evaluate pharmacokinetic parameter volume of distribution (Vd) in healthy adults to see if atropine will reach detectable concentrations in plasma following topical oral administration in gel formulation.
Calculate the pharmacokinetic parameter Vd after topical oral administration of atropine gel
Evaluate pharmacokinetic parameter clearance (CL) in healthy adults to see if atropine will reach detectable concentrations in plasma following topical oral administration in gel formulation.
Calculate the pharmacokinetic parameter CL after topical oral administration of atropine gel

Secondary Outcome Measures

Full Information

First Posted
November 22, 2021
Last Updated
November 1, 2022
Sponsor
University of Utah
search

1. Study Identification

Unique Protocol Identification Number
NCT05164367
Brief Title
Pharmacokinetics of Atropine Oral Gel
Official Title
Single-Dose Pharmacokinetics of Atropine Oral Gel in Healthy Adults
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Recruiting
Study Start Date
October 1, 2022 (Actual)
Primary Completion Date
October 2023 (Anticipated)
Study Completion Date
October 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Utah

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
To evaluate the single-dose pharmacokinetics of atropine gel formulation after topical administration in the oral cavity of healthy adults.
Detailed Description
This study is a single-dose, single-center, open-label study of the pharmacokinetics of atropine gel (0.01% w/w) after topical oral administration in healthy adults. Study participants will be recruited by Drs. Murphy, Darro, and Yellepeddi at the Center for Clinical and Translation Science (CCTS), University of Utah. Participants who meet eligibility criteria will be recruited in the study after signing informed consent. Each of the 10 participants will receive 1 gram of atropine gel (0.01% w/w) containing 0.1 mg atropine via self-administration of gel into the oral cavity. Dr. Yellepeddi is a licensed pharmacist in the State of Utah and will train subjects in the administration of atropine gel in the oral cavity. A series of timed blood samples (0, 5, 10, 15, 30, 60 minutes, and 2, 4, 6, 8, and 24 hours, 7 mL each time point) will be collected in commercial tubes, and plasma will be separated by centrifugation. The plasma samples will be stored frozen until further analysis by the Center for Human Toxicology (CHT), University of Utah.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cerebral Palsy, Sialorrhea
Keywords
Pharmacokinetics, Cerebral Palsy, Sialorrhea, Atropine sulfate gel

7. Study Design

Primary Purpose
Treatment
Study Phase
Early Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
0.1 mg of atropine
Arm Type
Experimental
Arm Description
1 gram of gel by topical application in the oral cavity once.
Intervention Type
Drug
Intervention Name(s)
Atropine sulfate gel (0.01%)
Other Intervention Name(s)
Atropine gel, mucoadhesive atropine gel
Intervention Description
A research nurse will measure 1 gram of gel using a calibrated measuring spoon and will provide it to the participant for self-administration.
Primary Outcome Measure Information:
Title
Evaluate pharmacokinetic parameter time to reach maximum plasma concentration (Tmax) in healthy adults to see if atropine will reach detectable concentrations in plasma following topical oral administration in gel formulation.
Description
Calculate the pharmacokinetic parameter Tmax after topical oral administration of 0.01% atropine gel.
Time Frame
The Tmax will be evaluated at timepoints 0, 5, 10, 15, 30, 60 minutes, and 2, 4, 6, 8, and 24 hours after administration of gel to the oral cavity.
Title
Evaluate pharmacokinetic parameter time to reach maximum plasma concentration (Cmax) in healthy adults to see if atropine will reach detectable concentrations in plasma following topical oral administration in gel formulation.
Description
Calculate the pharmacokinetic parameter Cmax after topical oral administration of atropine gel
Time Frame
The Cmax will be evaluated at timepoints 0, 5, 10, 15, 30, 60 minutes, and 2, 4, 6, 8, and 24 hours after administration of gel to the oral cavity.
Title
Evaluate pharmacokinetic parameter area under the curve (AUC) in healthy adults to see if atropine will reach detectable concentrations in plasma following topical oral administration in gel formulation.
Description
Calculate the pharmacokinetic parameter AUC after topical oral administration of atropine gel
Time Frame
The AUC will be evaluated at timepoints 0, 5, 10, 15, 30, 60 minutes, and 2, 4, 6, 8, and 24 hours after administration of gel to the oral cavity.
Title
Evaluate pharmacokinetic parameter volume of distribution (Vd) in healthy adults to see if atropine will reach detectable concentrations in plasma following topical oral administration in gel formulation.
Description
Calculate the pharmacokinetic parameter Vd after topical oral administration of atropine gel
Time Frame
The Vd will be evaluated at timepoints 0, 5, 10, 15, 30, 60 minutes, and 2, 4, 6, 8, and 24 hours after administration of gel to the oral cavity.
Title
Evaluate pharmacokinetic parameter clearance (CL) in healthy adults to see if atropine will reach detectable concentrations in plasma following topical oral administration in gel formulation.
Description
Calculate the pharmacokinetic parameter CL after topical oral administration of atropine gel
Time Frame
The CL will be evaluated at timepoints 0, 5, 10, 15, 30, 60 minutes, and 2, 4, 6, 8, and 24 hours after administration of gel to the oral cavity.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Provide written informed consent and authorization. Study participants must be able to complete consent, and all study evaluations written in the English language. Exclusion Criteria: Female subjects who are pregnant or nursing at the time of screening Chemotherapy or radiotherapy treatment within the last three months Severe renal impairment defined as estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2 calculated using the CKD-EPI creatinine equation: eGFR (mL/min/1.73 m2) = 141 x min(Scr/k, 1)α x max(Scr/k,1)-1.209 x 0.993Age x 1.018 [if female] x 1.159 [if black] Where, k=0.7 if female k=0.9 if male α=-0.329 if female α=-0.411 if male min=The minimum of Scr/k or 1 max=The maximum of Scr/k or 1 Scr = serum creatinine (mg/dL) Acute hepatitis in the prior 6 months, a prior history of cirrhosis, acute hepatic failure, or acute decompensation of chronic hepatic failure; and/or any of the following blood test results, for any individual, when assessed for eligibility: Bilirubin > 3 x upper limit of normal (ULN). [ULN for bilirubin = 1.4 mg/dL] Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) > 3 x ULN values used by the laboratory performing the test. [ULN for AST = 40 U/L, ULN for ALT = 60 U/L] Alkaline phosphatase (ALP) > 3 x ULN [ULN for ALP = 126 U/L) Deforming lesions of the oral cavity Previous head and/or neck radiotherapy Patients with a history of hypersensitivity reaction towards atropine and/or Carbopol 980 NF or any carbomers Patients with heart conditions such as congenital heart disease, heart failure, coronary heart disease, myocardial infarction, and arrhythmia Patients with acute glaucoma that may be exacerbated with atropine administration. Patients with partial pyloric stenosis or other diseases related to gastrointestinal obstruction. Patients diagnosed with urinary retention Treatment with any other investigational drug during the 30 days prior to enrollment into the study Patients receiving anticholinergic medications at baseline. Patients who are receiving immunosuppression Patients who are actively being treated for an infection Patients with a history of salivary gland obstruction or stones Patients with a history of chronic lung disease or chronic obstructive pulmonary disease (COPD) Patients with an artificial airway (tracheostomy) Patient taking monoamine oxidase inhibitors
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Venkata K. Yellepeddi, PhD
Phone
801-213-0701
Email
venkata.yellepeddi@hsc.utah.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Nancy Murphy, MD
Phone
801-587-9685
Email
Nancy.Murphy@hsc.utah.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Venkata K. Yellepeddi, PhD
Organizational Affiliation
University of Utah
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Utah
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84112
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Venkata K. Yellepeddi, PhD
Phone
801-213-0701
Email
venkata.yellepeddi@hsc.utah.edu
First Name & Middle Initial & Last Name & Degree
Nancy Murphy, MD
First Name & Middle Initial & Last Name & Degree
Natalie Darro, DO

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
30885525
Citation
Reid SM, Westbury C, Chong D, Johnstone BR, Guzys A, Reddihough DS. Long-term impact of saliva control surgery in children with disability. J Plast Reconstr Aesthet Surg. 2019 Jul;72(7):1193-1197. doi: 10.1016/j.bjps.2019.02.020. Epub 2019 Mar 2.
Results Reference
background
PubMed Identifier
31328797
Citation
Speyer R, Cordier R, Kim JH, Cocks N, Michou E, Wilkes-Gillan S. Prevalence of drooling, swallowing, and feeding problems in cerebral palsy across the lifespan: a systematic review and meta-analyses. Dev Med Child Neurol. 2019 Nov;61(11):1249-1258. doi: 10.1111/dmcn.14316. Epub 2019 Jul 22.
Results Reference
background
PubMed Identifier
20813020
Citation
Parkes J, Hill N, Platt MJ, Donnelly C. Oromotor dysfunction and communication impairments in children with cerebral palsy: a register study. Dev Med Child Neurol. 2010 Dec;52(12):1113-9. doi: 10.1111/j.1469-8749.2010.03765.x. Epub 2010 Aug 31.
Results Reference
background
PubMed Identifier
22881219
Citation
Reid SM, McCutcheon J, Reddihough DS, Johnson H. Prevalence and predictors of drooling in 7- to 14-year-old children with cerebral palsy: a population study. Dev Med Child Neurol. 2012 Nov;54(11):1032-6. doi: 10.1111/j.1469-8749.2012.04382.x. Epub 2012 Aug 9.
Results Reference
background
PubMed Identifier
31495925
Citation
Reid SM, Westbury C, Guzys AT, Reddihough DS. Anticholinergic medications for reducing drooling in children with developmental disability. Dev Med Child Neurol. 2020 Mar;62(3):346-353. doi: 10.1111/dmcn.14350. Epub 2019 Sep 8.
Results Reference
background
PubMed Identifier
26708211
Citation
Norderyd J, Graf J, Marcusson A, Nilsson K, Sjostrand E, Steinwall G, Arleskog E, Bagesund M. Sublingual administration of atropine eyedrops in children with excessive drooling - a pilot study. Int J Paediatr Dent. 2017 Jan;27(1):22-29. doi: 10.1111/ipd.12219. Epub 2015 Dec 27.
Results Reference
background
PubMed Identifier
22833553
Citation
Protus BM, Grauer PA, Kimbrel JM. Evaluation of atropine 1% ophthalmic solution administered sublingually for the management of terminal respiratory secretions. Am J Hosp Palliat Care. 2013 Jun;30(4):388-92. doi: 10.1177/1049909112453641. Epub 2012 Jul 24.
Results Reference
background
PubMed Identifier
17060265
Citation
De Simone GG, Eisenchlas JH, Junin M, Pereyra F, Brizuela R. Atropine drops for drooling: a randomized controlled trial. Palliat Med. 2006 Oct;20(7):665-71. doi: 10.1177/0269216306071702.
Results Reference
background
PubMed Identifier
29651363
Citation
Lawrence R, Bateman N. Surgical Management of the Drooling Child. Curr Otorhinolaryngol Rep. 2018;6(1):99-106. doi: 10.1007/s40136-018-0188-2. Epub 2018 Mar 20.
Results Reference
background
PubMed Identifier
28043733
Citation
Leung JG, Schak KM. Potential problems surrounding the use of sublingually administered ophthalmic atropine for sialorrhea. Schizophr Res. 2017 Jul;185:202-203. doi: 10.1016/j.schres.2016.12.028. Epub 2016 Dec 30. No abstract available.
Results Reference
background
PubMed Identifier
10914315
Citation
Singla AK, Chawla M, Singh A. Potential applications of carbomer in oral mucoadhesive controlled drug delivery system: a review. Drug Dev Ind Pharm. 2000 Sep;26(9):913-24. doi: 10.1081/ddc-100101318.
Results Reference
background
PubMed Identifier
17452085
Citation
Keegan G, Smart J, Ingram M, Barnes L, Rees G, Burnett G. An in vitro assessment of bioadhesive zinc/carbomer complexes for antimicrobial therapy within the oral cavity. Int J Pharm. 2007 Aug 1;340(1-2):92-6. doi: 10.1016/j.ijpharm.2007.03.023. Epub 2007 Mar 24.
Results Reference
background
PubMed Identifier
15196643
Citation
Kelly HM, Deasy PB, Busquet M, Torrance AA. Bioadhesive, rheological, lubricant and other aspects of an oral gel formulation intended for the treatment of xerostomia. Int J Pharm. 2004 Jul 8;278(2):391-406. doi: 10.1016/j.ijpharm.2004.03.022.
Results Reference
background
PubMed Identifier
24877167
Citation
Allison RR, Ambrad AA, Arshoun Y, Carmel RJ, Ciuba DF, Feldman E, Finkelstein SE, Gandhavadi R, Heron DE, Lane SC, Longo JM, Meakin C, Papadopoulos D, Pruitt DE, Steinbrenner LM, Taylor MA, Wisbeck WM, Yuh GE, Nowotnik DP, Sonis ST. Multi-institutional, randomized, double-blind, placebo-controlled trial to assess the efficacy of a mucoadhesive hydrogel (MuGard) in mitigating oral mucositis symptoms in patients being treated with chemoradiation therapy for cancers of the head and neck. Cancer. 2014 May 1;120(9):1433-40. doi: 10.1002/cncr.28553.
Results Reference
background
Citation
Alcon (2018). Viscotears® Liquid Gel [carbomer (polyacrylic acid)] - Patient Information Leaflet
Results Reference
background
Citation
Regulatory Information for Carbopol®* 971P NF Polymer & Carbopol® 71G NF Polymer. file:///C:/Users/u0840209/Downloads/TDS-328_Carbopol_971P_71G_Regulatory_PH_Version%20(1).pdf
Results Reference
background
PubMed Identifier
22298950
Citation
Zeller RS, Lee HM, Cavanaugh PF, Davidson J. Randomized Phase III evaluation of the efficacy and safety of a novel glycopyrrolate oral solution for the management of chronic severe drooling in children with cerebral palsy or other neurologic conditions. Ther Clin Risk Manag. 2012;8:15-23. doi: 10.2147/TCRM.S26893. Epub 2012 Jan 25.
Results Reference
background
PubMed Identifier
19843155
Citation
Reid SM, Johnson HM, Reddihough DS. The Drooling Impact Scale: a measure of the impact of drooling in children with developmental disabilities. Dev Med Child Neurol. 2010 Feb;52(2):e23-8. doi: 10.1111/j.1469-8749.2009.03519.x. Epub 2009 Oct 15.
Results Reference
background
PubMed Identifier
10830644
Citation
Jones JM, Watkins CA, Hand JS, Warren JJ, Cowen HJ. Comparison of three salivary flow rate assessment methods in an elderly population. Community Dent Oral Epidemiol. 2000 Jun;28(3):177-84. doi: 10.1034/j.1600-0528.2000.280303.x.
Results Reference
background
PubMed Identifier
6956596
Citation
Navazesh M, Christensen CM. A comparison of whole mouth resting and stimulated salivary measurement procedures. J Dent Res. 1982 Oct;61(10):1158-62. doi: 10.1177/00220345820610100901. No abstract available.
Results Reference
background
PubMed Identifier
28591387
Citation
Dias BLS, Fernandes AR, Maia HS Filho. Treatment of drooling with sublingual atropine sulfate in children and adolescents with cerebral palsy. Arq Neuropsiquiatr. 2017 May;75(5):282-287. doi: 10.1590/0004-282X20170033.
Results Reference
background
PubMed Identifier
32685247
Citation
Azapagasi E, Kendirli T, Perk O, Kutluk G, Oz Tuncer G, Teber S, Cobanoglu N. Sublingual Atropine Sulfate Use for Sialorrhea in Pediatric Patients. J Pediatr Intensive Care. 2020 Sep;9(3):196-200. doi: 10.1055/s-0040-1708552. Epub 2020 Apr 7.
Results Reference
background
PubMed Identifier
20541902
Citation
Rapoport A. Sublingual atropine drops for the treatment of pediatric sialorrhea. J Pain Symptom Manage. 2010 Nov;40(5):783-8. doi: 10.1016/j.jpainsymman.2010.02.007. Epub 2010 Jun 11.
Results Reference
background
Links:
URL
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d200bd44-9856-4104-a29e-a4cca3db6737
Description
Prescribing information of Cuvposa-glycopyrrolate liquid.

Learn more about this trial

Pharmacokinetics of Atropine Oral Gel

We'll reach out to this number within 24 hrs